Literature DB >> 2944959

Effect of antioxidants on primary alloantigen-induced T cell activation and proliferation.

G Chaudhri, I A Clark, N H Hunt, W B Cowden, R Ceredig.   

Abstract

Because oxygen-centered free radicals are involved in cell-mediated immune responses, we examined the possibility that these reactive species could also have a role in the lymphoproliferative response to alloantigens in the mixed lymphocyte culture (MLC). Three classes of agents that prevent the formation, or damaging effects, of oxygen radicals were tested: the non-permeant electron acceptor ferricyanide; the iron chelators desferrioxamine, desferrithiocin, octanohydroxamic acid, and pyridoxal isonicotinoyl hydrazone, which are thought to be capable of preventing the iron-catalyzed reduction of H2O2 to more reactive species; and the lipid-soluble free radical scavenger butylated hydroxyanisole. These compounds inhibited the proliferation of all potential responder cells in the MLC in a dose-dependent manner. Inhibition was observed only if these agents were present early (less than 40 hr) in the MLC; if added later, their effects were significantly reduced. In contrast, the interleukin 2 (IL 2)-dependent proliferation of CTLL-2 cells or Con A blasts was not affected by these compounds at concentrations that inhibited proliferation in MLC by greater than 90%. Interleukin 1 (IL 1) production by peritoneal exudate cells and IL 2 and IL 1 levels in MLC were not affected by any of the agents tested. By flow microfluorometry, the expression of IL 2 receptors on stimulated T cells was found to be inhibited in the presence of these drugs. Taken together, the data point to an important role for free radical-mediated processes during the early stages of T lymphocyte activation, before IL 2 receptor expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2944959

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Iron chelators and lymphocyte proliferation.

Authors:  N H Hunt
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

2.  Peroxiredoxin II regulates effector and secondary memory CD8+ T cell responses.

Authors:  Ryan D Michalek; Katie E Crump; Ashley E Weant; Elizabeth M Hiltbold; Daniel G Juneau; Eun-Yi Moon; Dae-Yeul Yu; Leslie B Poole; Jason M Grayson
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

Review 3.  ROS function in redox signaling and oxidative stress.

Authors:  Michael Schieber; Navdeep S Chandel
Journal:  Curr Biol       Date:  2014-05-19       Impact factor: 10.834

Review 4.  Fueling immunity: insights into metabolism and lymphocyte function.

Authors:  Erika L Pearce; Maya C Poffenberger; Chih-Hao Chang; Russell G Jones
Journal:  Science       Date:  2013-10-11       Impact factor: 47.728

5.  Proliferation in vitro of Lyt2-,L3T4- thymocytes shows responsiveness to interleukin 1.

Authors:  G Chaudhri; I A Clark; R Ceredig
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

6.  Inhibition of murine T-cell responses by anti-oxidants: the targets of lipo-oxygenase pathway inhibitors.

Authors:  J Dornand; M Gerber
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

7.  Antioxidants can prevent cerebral malaria in Plasmodium berghei-infected mice.

Authors:  C M Thumwood; N H Hunt; W B Cowden; I A Clark
Journal:  Br J Exp Pathol       Date:  1989-06

8.  The role of oxidative stress in the pathogenesis of asthma.

Authors:  You Sook Cho; Hee-Bom Moon
Journal:  Allergy Asthma Immunol Res       Date:  2010-04-29       Impact factor: 5.764

9.  Suppressive effects of a novel antioxidant compound on human T cell functions in vitro.

Authors:  J K Kalsi; K Clay; D Rickard; N D Hall
Journal:  Agents Actions       Date:  1993

10.  Antioxidant treatment reduces expansion and contraction of antigen-specific CD8+ T cells during primary but not secondary viral infection.

Authors:  Nathan G Laniewski; Jason M Grayson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.